Valproic Acid TDM Calculator (Therapeutic Range and Dose Correction)

Medically reviewed by Dr. Taimoor Asghar, physician.

Interpret valproate levels for epilepsy (50 to 100 microgram/mL) and acute bipolar mania (50 to 125), compute proportional dose corrections rounded to practical tablet strengths, flag patients whose total level hides a high free fraction, and get labelling-based starting doses. Use the calculator above, then read the guide below to interpret your result and its limitations.

Therapeutic ranges by indication

Valproate is used across epilepsy, bipolar disorder, and migraine prophylaxis, and the target blood level differs by indication. For epilepsy the widely used therapeutic range is 50 to 100 microgram/mL, a window supported by the drug labelling and by decades of monitoring practice. For acute bipolar mania the range extends higher, 50 to 125 microgram/mL, reflecting the doses studied in the mania trials. Migraine prophylaxis does not have a firmly established range, and monitoring there is less about hitting a number than about confirming adherence and avoiding toxicity.

These ranges describe total valproate, the sum of bound and free drug that the laboratory reports. Most patients achieve seizure or mood control somewhere inside the range, but the range is a guide rather than a guarantee: some patients respond below 50, and some need levels near the top. Clinical response and side effects always outrank the number. A patient who is seizure-free at 45 microgram/mL with no side effects is better managed than a patient pushed to 80 who is tremulous and nauseated.

Timing of the sample matters as much as the number. Valproate levels should be drawn as troughs, just before the next scheduled dose, and serial levels should be compared trough to trough. A level drawn a few hours after a dose can be substantially higher than the trough and will mislead any dose calculation. After starting therapy or changing the dose, wait 2 to 4 days before rechecking, which allows roughly five half-lives for the new steady state to establish itself.

Protein binding and the free-fraction problem

Valproate is approximately 90 percent bound to albumin, and binding is saturable: as the total level rises, the free fraction rises disproportionately because binding sites fill up. This means the relationship between total and free drug is not fixed. At low totals the free fraction is near 10 percent, but at high totals, or when albumin is low, the free share can double or more. The laboratory reports the total, so in exactly the patients where the total is least reliable, the number on the slip is the one clinicians are tempted to trust.

Three common situations raise the free fraction. First, hypoalbuminaemia below about 3.5 g/dL, seen in liver disease, nephrotic syndrome, malnutrition, and critical illness. Second, older age: patients over 65 have reduced albumin and altered binding even when the albumin looks borderline. Third, liver or kidney disease, where endogenous binding competitors accumulate. In any of these, a total level in the therapeutic range can accompany a free level well into the toxic zone, producing tremor, sedation, confusion, or hyperammonaemic encephalopathy despite a reassuring slip.

This calculator flags these situations explicitly. If albumin is below 3.5 g/dL, the patient is 65 or older, or liver or kidney disease is present, it shows a free-fraction warning advising a measured free valproate level before adjusting on the total alone. The therapeutic range for free valproate is roughly 5 to 15 microgram/mL. Unlike phenytoin there is no widely validated correction equation for valproate, because its saturable binding defeats simple algebra, so the free assay is the answer when binding is abnormal.

Proportional dose correction

Valproate follows approximately linear kinetics within the usual dosing range, which makes proportional dose adjustment a reasonable first estimate: new total daily dose equals current total daily dose times (target level divided by measured level). A patient taking 1,000 mg daily with a trough of 40 microgram/mL and a target of 75 would move to about 1,875 mg daily. The calculator rounds to the nearest 25 mg to match practical dosing increments and checks the result against the labelling maximum.

The labelling maximum is 60 mg/kg/day, which for a 70 kg adult is 4,200 mg daily. Doses above this need explicit clinical justification and close monitoring. In practice most adults are maintained well below it: typical maintenance for epilepsy is 1,000 to 2,000 mg daily in divided doses, and the extended-release formulation allows once-daily dosing that many patients prefer. If the proportional estimate exceeds the maximum, the calculator says so plainly rather than presenting an unsafe number as a recommendation.

Two caveats keep the estimate honest. First, the saturable protein binding means the linear assumption weakens at higher levels: pushing from 100 toward 125 raises the free level more than the total suggests. Second, enzyme-inducing co-medications such as carbamazepine, phenytoin, and phenobarbital roughly double valproate clearance, so levels fall when an inducer is added and rise when one is stopped. Any dose correction should be rechecked with a trough level 2 to 4 days later, and interacting drugs should be reviewed before the dose is blamed for an unexpected level.

Starting doses and titration

When no level is available yet, the calculator gives labelling-based starting guidance from the weight. For epilepsy the labelling start is 10 to 15 mg/kg/day in two or three divided doses, which for a 70 kg adult is 700 to 1,050 mg daily, with increases of 5 to 10 mg/kg/week toward effect. For acute mania the delayed-release labelling starts at 750 mg daily in divided doses, while the extended-release form starts at 25 mg/kg/day once daily, titrated as quickly as tolerated toward the target level.

Titration speed is a clinical judgement that balances urgency against tolerability. Gastrointestinal upset, tremor, and sedation are the common early complaints and often settle as the body adjusts, but pushing the dose too fast drives dropouts. A practical approach is to advance weekly in epilepsy and somewhat faster in acute mania, where rapid control matters more, always watching for the warning signs of serious toxicity: unusual bruising or bleeding (thrombocytopenia), severe abdominal pain with vomiting (pancreatitis), and excessive sleepiness or confusion (hyperammonaemia).

The first trough level should be drawn 2 to 4 days after starting or after reaching a stable dose, then entered into the calculator for interpretation and correction. Early monitoring also establishes the individual's level-to-dose relationship, which varies widely: two patients on the same mg/kg dose can differ twofold in blood level because of differences in clearance, age, and interacting drugs. That individual relationship, once known, makes all future adjustments more precise.

Safety: liver, pancreas, platelets, and pregnancy

Valproate carries several serious risks that monitoring must cover alongside levels. Hepatotoxicity, including fatal hepatic failure, is most feared in the first six months, particularly in young children on polytherapy and in patients with mitochondrial disorders. Baseline and periodic liver function tests are standard, and the drug should be stopped promptly if there are signs of hepatic dysfunction. Pancreatitis can occur at any time, even years into therapy, and severe abdominal pain with vomiting needs urgent assessment rather than reassurance.

Thrombocytopenia is dose-related and more common in women and at higher levels; platelet counts deserve checking when levels are pushed upward or when bruising appears. Hyperammonaemic encephalopathy can occur with normal liver function tests, presenting as confusion, lethargy, or vomiting, and is an under-recognised cause of deterioration in valproate-treated patients. Carnitine supplementation is sometimes used in high-risk situations, though the evidence base is modest.

Pregnancy deserves special emphasis. Valproate is one of the most teratogenic commonly used drugs, with major congenital malformation rates around 10 percent and well-documented effects on child neurodevelopment including lower IQ and autism risk. Regulatory agencies in the UK and EU have progressively restricted its use in women of childbearing potential: it should be avoided in pregnancy unless no suitable alternative exists, and then only with specialist oversight, high-dose folate, and detailed foetal monitoring. Any dose decision in a woman who could become pregnant must weigh seizure or mood stability against these risks explicitly.

Intravenous loading in status epilepticus

In status epilepticus, oral titration is too slow, and intravenous valproate offers a loading option. The labelling-derived loading range is 20 to 25 mg/kg given intravenously, which for a 70 kg adult is 1,400 to 1,750 mg, infused over about an hour with monitoring. This is strictly a hospital intervention, used when benzodiazepines have not terminated the seizure and a second-line agent is needed.

Intravenous valproate has practical advantages in this setting: it lacks the cardiovascular toxicity and tissue injury risk of intravenous phenytoin, and it does not require the same slow infusion with cardiac monitoring, though monitoring remains prudent. It is compatible with most emergency protocols as an alternative to levetiracetam, phenytoin/fosphenytoin, or lacosamide, with the choice driven by the patient's history, comorbidities, and what has worked before.

After loading, maintenance intravenous or oral dosing continues with level monitoring, transitioning to oral therapy once the patient is stable. The calculator shows the weight-based loading range whenever weight is entered, as a reference for the emergency setting. Dosing in status epilepticus follows local hospital protocol and specialist direction; the calculator supports the arithmetic, it does not choose the drug.

Sources

• Depakine (sodium valproate) Summary of Product Characteristics: therapeutic range 50 to 100 mg/L for epilepsy control; 40 to 100 mg/L quoted in older labelling. Electronic medicines compendium. medicines.org.uk
• Bowden CL, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA. 1994;271(12):918-924. doi:10.1001/jama.1994.03510360046036 (target range 50 to 125 microgram/mL in mania trials).

Frequently asked questions

What is the therapeutic range for valproic acid?

For epilepsy the widely used range is 50 to 100 microgram/mL of total valproate; for acute bipolar mania it is 50 to 125 microgram/mL. These are trough ranges, drawn just before the next dose. Individual patients vary, so clinical response and side effects should guide dosing alongside the number.

Why might my valproate level look fine while I feel toxic?

Valproate is about 90 percent bound to albumin, and only the free fraction is active. When albumin is low, in older patients, or in liver or kidney disease, the free share rises while the total stays in range, so tremor, sedation, or confusion can occur with a reassuring total level. A measured free valproate level (therapeutic roughly 5 to 15 microgram/mL) resolves the question.

How do I adjust the valproate dose from a level?

As a first estimate, multiply the current total daily dose by (target level divided by measured level), then round to the nearest 25 mg. Check the result against the labelling maximum of 60 mg/kg/day, recheck a trough 2 to 4 days after the change, and review interacting drugs such as carbamazepine or phenytoin that alter valproate clearance.

What dose of valproate do you start with?

For epilepsy the labelling start is 10 to 15 mg/kg/day in divided doses, increased by 5 to 10 mg/kg/week. For acute mania it is 750 mg daily in divided doses (delayed-release) or 25 mg/kg/day once daily (extended-release), titrated as quickly as tolerated. The maximum is 60 mg/kg/day.

Is valproate safe in pregnancy?

No, it is one of the most teratogenic drugs in common use, with major malformation rates around 10 percent and adverse effects on child neurodevelopment. It should be avoided in pregnancy and in women of childbearing potential unless no suitable alternative exists, and then only under specialist care with high-dose folate and detailed monitoring.

What are the serious side effects to watch for?

Seek urgent assessment for signs of liver failure (jaundice, unusual fatigue, vomiting), pancreatitis (severe abdominal pain with vomiting), unusual bruising or bleeding (low platelets), and confusion or excessive sleepiness (possible hyperammonaemia, which can occur even with normal liver tests). Common milder effects include tremor, weight gain, hair thinning, and stomach upset.

Clinical sources: Depakine Summary of Product Characteristics (electronic medicines compendium); Bowden CL et al. JAMA. 1994;271(12):918-924.